Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 1, 2012, Pages 52-59

  Howard, Catherine G ^a   Mitchell, Kenneth D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Aliskiren; Arterial blood pressure; Kidney; Renal hemodynamics; Renin angiotensin system; Sodium excretion; Urine flow

Indexed keywords

ALISKIREN; ANGIOTENSIN II; CANDESARTAN; CYTOCHROME P450 1A1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; INHIBITION KINETICS; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; MALIGNANT HYPERTENSION; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM URINE LEVEL; TRANSGENIC RAT; URINARY EXCRETION;

EID: 83455176743     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00187.2011     Document Type: Article

References (30)

1. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109: 2619-2625, 1996.
2. Cervenka L, Wang CT, Mitchell KD, Navar LG. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 33: 102-107, 1999.
3. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52: 130-136, 2008.
4. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res 33: 279-287, 2010.
5. Feldman DL, Schuetz H, Persohn E, Muller DN. Light microscopy autoradiographic localization of the renin inhibitor aliskiren in rat kidneys (Abstract). Hypertension 56: e109, 2010.
6. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, Katsurada A, Tran DV, Kobori H, Navar LG. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol 295: F772-F779, 2008.
7. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ, Mitchell KD. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG IIdependent malignant hypertension. Am J Physiol Renal Physiol 292: F1858-F1866, 2007.
8. Guan S, Fox J, Mitchell KD, Navar LG. Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 20: 763-767, 1992.
9. Howard CG, Mullins JJ, Mitchell KD. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Med Sci 341: 383-387, 2011.
10. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol 143: 117-130, 2004.
11. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276: 36727-36733, 2001.
12. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
13. Kopkan L, Kramer HJ, Husková Z, Vanourková Z, Skaroupková P, Thurmová M, Cervenka L. The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 23: 1531-1539, 2005.
14. Lijnen PJ, Petrov VV. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. Methods Find Exp Clin Pharmacol 25: 541-564, 2003.
15. Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 54: 985-988, 1975.
16. Milani CJ, Kobori H, Mullins JJ, Mitchell KD. Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am J Med Sci 340: 389-394, 2010.
17. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289: F1210-F1216, 2005.
18. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 7: 74-86, 2006.
19. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 17: 412-422, 1997.
20. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension 57: 355-362, 2011.
21. Opay AL, Mouton CR, Mullins JJ, Mitchell KD. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 291: F612-F618, 2006.
22. Ortiz RM, Graciano ML, Mullins JJ, Mitchell KD. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 293: F1584-F1591, 2007.
23. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 289: F754-F759, 2005.
24. Peters J, Schlüter T, Riegel T, Peters BS, Beineke A, Maschke U, Hosten N, Mullins JJ, Rettig R. Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism. Am J Physiol Heart Circ Physiol 297: H1845-H1852, 2009.
25. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-576, 2005.
26. Prieto MC, Williams DE, Liu L, Kavanagh KL, Mullins JJ, Mitchell KD. Enhancement of renin and prorenin receptor in the collecting duct of Cyp1a1-Ren2 rats contribute to development and progression of malignant hypertension. Am J Physiol Renal Physiol 300: F581-F588, 2011.
27. 5-ANG II-infused rats. Am J Physiol Renal Physiol 296: F1067-F1071, 2009.
28. Vanourková Z, Kramer HJ, Husková Z, Vanecková I, Opocenský M, Chábová VC, Tesar V, Skaroupková P, Thumová M, Dohnalová M, Mullins JJ, Cervenka L. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1- Ren-2 transgenic rats with inducible hypertension. J Hypertens 24: 2465-2472, 2006.
29. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 4: 971-981, 2008.
30. Williams DE, Prieto MC, Mullins JJ, Navar LG, Mitchell KD. AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet. Am J Med Sci 339: 356-361, 2010.